




Europäisches
Patentamt

European
Patent Office

PCT/EP 03 / 1 4 5 0 7
Office européen
des brevets



Bescheinigung

Certificate

Attestation

Die angehefteten Unterlagen stimmen mit der ursprünglich eingereichten Fassung der auf dem nächsten Blatt bezeichneten europäischen Patentanmeldung überein.

The attached documents are exact copies of the European patent application described on the following page, as originally filed.

Les documents fixés à cette attestation sont conformes à la version initialement déposée de la demande de brevet européen spécifiée à la page suivante.

Best Available Copy

Patentanmeldung Nr. Patent application No. Demande de brevet n°

03001242.1

**PRIORITY
DOCUMENT**
SUBMITTED OR TRANSMITTED IN
COMPLIANCE WITH RULE 17.1(a) OR (b)

Der Präsident des Europäischen Patentamts;
Im Auftrag

For the President of the European Patent Office

Le Président de l'Office européen des brevets
p.o.

R C van Dijk



Anmeldung Nr:
Application no.: 03001242.1
Demande no:

Anmeldetag:
Date of filing: 21.01.03
Date de dépôt:

Anmelder/Applicant(s)/Demandeur(s):

BIOMAY Produktions- und Handels-
Aktiengesellschaft
Vienna Biocenter,
Dr.Bohr-Gasse 7b
1030 Wien
AUTRICHE

Bezeichnung der Erfindung/Title of the invention/Titre de l'invention:
(Falls die Bezeichnung der Erfindung nicht angegeben ist, siehe Beschreibung.
If no title is shown please refer to the description.
Si aucun titre n'est indiqué se référer à la description.)

Process for the preparation of hypoallergenic mosaic proteins

In Anspruch genommene Priorität(en) / Priority(ies) claimed /Priorité(s)
revendiquée(s)
Staat/Tag/Aktenzeichen/State/Date/File no./Pays/Date/Numéro de dépôt:

Internationale Patentklassifikation/International Patent Classification/
Classification internationale des brevets:

C07K14/00

Am Anmeldetag benannte Vertragsstaaten/Contracting states designated at date of
filing/Etats contractants désignées lors du dépôt:

AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL
PT SE SI SK TR LI

LEDERER & KELLER

Patentanwälte - European Patent Attorneys
European Trademark Attorneys

EPO - Munich
67
21. Jan. 2003

DR. A. VAN DER WERTH
(1934 - 1974)

DR. FRANZ LEDERER
Dipl.-Chem.

DR. GÜNTHER KELLER
Dipl.-Biol.

DR. MICHAEL BEST
Dipl.-Chem.

DR. STEPHAN TEIPEL
Dipl.-Chem.

80538 MÜNCHEN
Prinzregentenstraße 16
Telefon (089) 21 23 99 0
Telefax (089) 21 23 99 22
E-Mail info@lederer-keller.de

January 21, 2003

BIOMAY Produktions- und Handels-Aktiengesellschaft
Vienna Biocenter
Dr. Bohr-Gasse 7b
A-1030 Wien
Österreich

Process for the preparation of hypoallergenic mosaic antigens

The present invention relates to mosaic antigens derived from naturally occurring allergens, in particular timothy grass pollen allergen Phl p 2. The mosaic antigens display reduced allergenic activity and are useful as allergy vaccines for the treatment of sensitized allergic patients and for prophylactic vaccination.

A large percentage of the population suffers from IgE-mediated allergies. Those patients suffer from allergic reactions against several antigens. A high percentage of the allergic reactions are caused by plant pollen. The symptoms of allergy like allergic rhinoconjunctivitis, asthma, dermatitis and even anaphylactic shock are due to IgE recognition of allergens. The IgE molecules are largely responsible for the symptoms of allergic reactions such as hay fever, asthma and hives.

The IgE molecules bind to an allergen like e.g. plant pollen. The tail region of the IgE molecule, the Fc part binds to Fc receptors which are mainly located on the surface of mast cells in tissues and basophils in the blood. Antigen binding triggers the mast cells or basophils to secrete a variety of cytokines and biologically active compounds, especially

histamine. These molecules cause blood vessels to dilate and become leaky which in turn helps white blood cells, antibodies and complements' components to enter sites of reaction. Those molecules are on the other hand largely responsible for the symptoms of allergic reactions. There are different degrees of allergic reactions which range from slight itching of the eyes and the symptoms of a slight cold over severe pains to live-threatening symptoms like anaphylactic shock which may occur for example after the sting of a bee.

In order to avoid these allergic reactions allergy vaccines have been developed which are based on the application of small amounts of hypoallergenic compounds. It is believed that by applying hypoallergenic vaccines IgG antibodies are produced which react with the allergen immediately after the individual has come into contact with the allergen. By those so-called blocking antibodies a contact between the allergen and the IgE molecules present in the patient's body is largely avoided. Therefore the reaction between the allergen and the mast cells mediated by IgE molecules is largely avoided.

In the field of therapy of allergic reactions different vaccines have been used. Formerly small amounts of the allergen have been applied to the patients. With the development of genetic engineering recombinant allergens may be used for vaccination. A major disadvantage of such allergen-containing vaccines is that the application of such vaccines causes in the patient unwanted side-effects. If for example the allergen against which the patient is allergic is applied subcutaneously to the patient an unwanted side-effect like itching up to anaphylatic shock can occur since the IgE antibodies present in the patient's body react with the allergen and cause the allergic reaction.

In order to overcome the undesired side-effects a process for the preparation of an hypoallergenic mosaic antigen derived from an allergen is disclosed whereby

- a) in a first step the allergen is split into at least two parts and the IgE reactivity of each part is determined and
- b) in a second step those parts of the allergen which have no detectable IgE reaction are combined to a mosaic antigen which comprises the amino acids of the allergen but the order of the amino acids of the mosaic antigen is different from that of the naturally occurring allergen.

The term "hypoallergenic mosaic antigen" provided by the present process means that the antigen comprises substantially all amino acids of the naturally occurring allergen. The difference compared with the naturally occurring antigen is, however, that the allergen is in a first step split into different parts. When the amino acid sequence of the allergen is known it is common general knowledge of a person skilled in the art to prepare peptides of varying lengths from the antigen. The peptides may either be prepared by chemical synthesis which is well-known in the art. Alternatively the peptides can be easily prepared by Polymerase Chain Reaction since suitable primers can be easily synthesized when the sequence is known.

The reactivity of each part of the allergen which is present as a peptide or polypeptide has to be determined. This can be done by reacting the peptide with sera from patients which are allergic against the naturally occurring allergen. The IgE antibodies present in such sera will react with the peptide if an IgE epitope is present on the peptide. If there are, however, no linear IgE epitopes or if conformational IgE epitopes are destroyed by separating the whole naturally occurring allergen there will be no binding of IgE with the peptide. The IgE antibodies can subsequently easily be detected by reaction with specific anti-antibodies which bind to the IgE antibody. Those anti-antibodies are usually labeled for detection.

It is an important aspect of the present invention to divide the allergen into such parts which do not react with IgE antibodies. If a part of the allergen still reacts with IgE antibodies in a substantial amount such parts of the allergen should not be used for the preparation of the mosaic antigen. It is advisable to test the parts of the naturally occurring antigen to be used in the mosaic antigen with sera from different allergic patients since there may be variations with regard to specificity and amount of IgE concentration in each serum.

When the allergen has been split up into several parts which do not have any detectable IgE reactivity those parts are newly arranged in order to provide the mosaic antigen. That the part of the allergen does not have a substantial IgE reactivity means that the IgE reactivity of the whole, naturally occurring allergen is tested with preferably at least five sera from allergic patients and the parts thereof are tested as well. The binding of IgE molecules to the allergen and the parts thereof is determined quantitatively and the IgE reactivity of the part has to be reduced to not more than 10%, preferably not more than 5% of the value obtained for the naturally occurring allergen.

The rearrangement of the parts of the naturally occurring allergen to the mosaic antigen means in the simplest case that the allergen is split up into two parts, namely part A having the N-terminus and ending at the cleavage side and part B starting with the cleavage side and ending with the carboxy terminus of the polypeptide. Cleavage site means the position in the polypeptide where one part ends and another part starts. If both parts of the naturally occurring antigen do not have a substantial IgE reactivity the two parts are rearranged in such a manner that now part B represents the N-terminus and part A represents the C-terminus.

When the naturally occurring allergen is split up into three parts having the naturally occurring order A, B and C there are several mosaic antigens possible, namely for example C, B, A; or A, C, B. The more parts are formed the more options for providing mosaic antigens are provided. In a preferred embodiment of the present invention it is avoided to combine parts which are localized in adjacent positions in the naturally occurring allergen, e.g. C, A, B. The reason therefore is that IgE binding epitopes may be formed again on the mosaic antigen. It is, however, essential that the mosaic antigen contains substantially all amino acids of the naturally occurring antigen. Certainly some amino acids which do clearly have no functions may be deleted or some amino acids may be deleted caused by production reasons, but as much as possible amino acids should be maintained. Moreover the mosaic antigen may also comprise amino acids used for production purposes. Preferably in the parts of the naturally occurring allergen which are reorganized in the mosaic antigen are as large as possible. The cleavage sites are preferably selected in order to destroy the IgE epitopes whereby the IgE epitopes are maintained as far as possible.

In a preferred embodiment the process is used with allergens of group 2. Preferred group 2 allergens are described in the following publication:

Freidhoff LR, Ehrlich-Kautzky E, Grant JH, Meyers DA, Marsh DG. A study of the human immune response to *Lolium perenne* (rye) pollen and its components, Lol p I and Lol p II (rye I and rye II). I. Prevalence of reactivity to the allergens and correlations among skin test, IgE antibody, and IgG antibody data. *J Allergy Clin Immunol* 1986, 78, 1190-1201.

Freidhoff LR, Ehrlich-Kautzky E, Meyers DA, Marsh DG. A study of the human immune response to *Lolium perenne* (rye) pollen and its components, Lol p I and Lol p II (Rye I and Rye II). II. Longitudinal variation of antibody levels in relation to symptomatology and pollen

exposure and correction of seasonally elevated antibody levels to basal values. *J Allergy Clin Immunol* 1987, 80, 646-655. Ansari AA, Shenbagamurthi P, Marsh DG. Complete amino acid sequence of a *Lolium perenne* (perennial rye grass) pollen allergen, Lol p II. *J Biol Chem* 1989, 264, 11181-11185. Dolecek C, Vrtala S, Laffer S, Steinberger P, Kraft D, Scheiner O, Valenta R. Molecular characterization of Phl p II, a major timothy grass (*Phleum pratense*) pollen allergen. *FEBS Lett* 1993, 335, 299-304.

In an especially preferred embodiment the allergen used for the mosaic antigen is the timothy grass pollen allergen Phl p 2. The sequence of the grass pollen allergen Phl p 2 is disclosed in WO 94/23035. A more detailed description of the Phl p 2 from timothy grass pollen is provided in De Marino et al., *Structure* (1999) Vol. 7, No. 8, p. 943-952. The Phl p 2 antigen is preferred since it reacts with serum IgE from about 70% of grass pollen allergic individuals and elicits histamine release from basophils of sensitized patients.

In the course of the present invention it has been found that the Phl p 2 allergen is preferably split into three peptides, namely peptide 1 having amino acids 1-33, peptide 2 having amino acids 34-64 and peptide 3 having amino acids 65-96. By rearranging the peptides in the order 1, 3 and 2 a mosaic antigen is provided which can be used for hypoallergenic vaccination. This mosaic antigen has the advantage that a sufficient amount of blocking IgE antibodies is produced, but the undesired side-reactions associated with the vaccination are nearly completely avoided.

The amino acid sequence of the preferred mosaic allergen has SEQ ID NO:1. The DNA coding for this preferred mosaic allergen has SEQ ID NO:2.

The mosaic allergen provided by the present disclosure can preferably be used for the preparation of a medicament for the treatment of an allergic reaction. The preferred Phl p 2 mosaic antigen can be used for the preparation of a medicament for the treatment of grass pollen allergy. Since the Phl p 2 is an antigen against which a large percentage of allergic patients have formed IgE antibodies the mosaic antigen is very helpful in the treatment of patients suffering from hay fever.

A mosaic antigen as prepared by the described process can be formulated as a medicament for the treatment of an allergic reaction. The main component is the mosaic antigen which is preferably administered together with an adjuvant. There are several adjuvants which are suitable for the application to humans like e.g. aluminium hydroxide gel. In another embodiment of the present invention it is also possible to link the mosaic antigen directly by covalent binding to another component which generally enhances the immunologic reaction of the body.

It is also possible to use a DNA coding for a mosaic antigen or a DNA sequence complementary thereto as a DNA vaccine. For nucleic acid vaccines a suitable polynucleotide sequence is inserted into the target cells. In addition to the sequence coding for the mosaic antigen such a DNA vaccine may also contain regulatory elements like promoters, ribosome binding sites or termination sequences. Such DNA sequences should preferably be incorporated into a suitable carrier which allows the DNA to come to the protein synthesizing machinery of the cells.

A mosaic antigen as described in detail herein is preferably intended for human application. It is, however, also possible to use the mosaic antigen for valuable animals like pets (e.g. dogs or cats) or horses.

The figures and tables describe preferred embodiments of the present invention:

Figure 1: Comparison of the IgE reactivity of synthetic Phl p 2-derived peptides and complete rPhl p 2 (recombinantly produced wild type allergen). Nitrocelluloses containing (A) dotted Phl p 2 peptides (P1, P2, P3), human serum albumin (HSA), a control peptide (P), and a non-cross-reactive timothy grass pollen allergen (rPhl p 5) and (B) rPhl p 5 and Phl p 2 (rPhl p 2) were exposed to sera from 35 grass pollen allergic patients (1-35) and to serum from a non-allergic individual (N).

Figure 2: Schematic representation of recombinant his-tagged Phl p 2 wildtype and recombinant his-tagged Phl p 2 mosaic. The position of the three peptides is indicated.

Figure 3: DNA sequence of the primers used for the construction of the Phl p 2 mosaic and schematic representation of PCR approach used for the assembly of the cDNA coding for the rPhl p 2 mosaic. The Nde I and Eco R I restriction sites are underlined in primer P2/1 and P2/6, respectively. The primers correspond to SEQ ID NO:6 to SEQ ID NO:11.

Figure 4: cDNA (SEQ ID NO:2) and deduced amino acid sequence (SEQ ID NO:1) and of the his-tagged Phl p 2 mosaic. Aminoacids are displayed in the single letter code, base pair and amino acid numbers are shown on the right margin.

Figure 5: Purity of rPhl p 2 mosaic and rPhl p 2. Comassie stained gel containing Phl p 2 (lane P2), Phl p 2 mosaic (lane P2M) and a molecular weight marker (lane M).

Figure 6: Mass spectroscopical analysis of purified rPhl p 2 mosaic (A) and rPhl p 2 (B). The mass/charge ratio is shown on the x-axis and the signal intensity is expressed as percentage of the most intensive signal obtained in the investigated mass range.

Figure 7: Comparison of the IgE binding capacity of rPhl p 2 (P2) and the rPhl p 2 mosaic (P2M). Nitrocellulose dotted rPhl p 2 (P2) and rPhl p 2 mosaic (P2M), as well as human serum albumine (HSA) were probed with serum from 12 Phl p 2-reactive grass pollen allergic patients (1-12). Bound IgE antibodies were detected with ^{125}I -labeled anti-human IgE antibodies and visualized by autoradiography.

Figure 8: Reduced allergenic activity of rPhl p 2 mosaic determined by basophil histamine release. Basophils from a grass pollen allergic patient were exposed to increasing concentrations of rPhl p 2 and rPhl p 2 mosaic (x-axis). Histamine release is expressed as percentage of total histamine release on the y-axis.

Figure 9: Rabbit anti-rPhl p 2 mosaic antibodies recognize the rPhl p 2 wildtype allergen. Rabbit antisera raised against the rPhl p 2 mosaic (αP2M), KLH-coupled mosaic ($\alpha\text{P2M-KLH}$) and rPhl p 2 ($\alpha\text{Phl p 2}$) as well as buffer (C) were exposed to dot-blotted KLH, human serum albumin (HSA), rPhl p 2 (P2) and rPhl p 2 mosaic (P2M). Bound rabbit antibodies were detected with ^{125}I -labeled donkey anti-rabbit IgG and visualized by autoradiography.

Table 1: Characteristics of Phl p 2-derived synthetic peptides. Sequence, number of amino acids, position in the Phl p 2 allergen, molecular weight and isoelectric point of the peptides are displayed. Peptide 1 corresponds to SEQ ID NO:3, Peptide 3 corresponds to SEQ ID NO:4 and Peptide 2 corresponds to SEQ ID NO:5.

Table 2: Immediate type skin reactions to complete rPhl p 2 and to Phl p 2 mosaic (P2M). Two timothy grass pollen allergic patients (Individual 1,2) were tested for skin reactivity with P2 and P2M. The mean wheal diameters (mm) are displayed for five different concentrations of rPhl p 2 and Phl p 2 mosaic, as well as for timothy grass pollen extract and histamine.

Table 3: Inhibition of grass pollen allergic patients IgE binding to rPhl p 2 by rabbit α P2M and rabbit α P2 antibodies. The percentage inhibition of IgE binding is displayed for 5 patients.

The invention is further illustrated by the following examples:

Example 1: Synthetic Phl p 2-derived peptides lacking allergenic activity

In order to identify Phl p 2 fragments without allergenic activity, peptides, each comprising about 1/3 of the Phl p 2 protein were chemically synthesized (Table 1). The peptides had a length between 32 and 34 aminoacids with molecular weights of around 3.7 kDa and together covered the complete Phl p 2 amino acid sequence.

The three peptides were synthesized using Fmoc (9-fluorenylmethoxycarbonyl)-strategy with HBTU (2-(1H-benzotriazol-1-yl) 1,1,3,3, tetramethyluronium hexafluorophosphat)-activation (0.1 mmol small-scale cycles) on the Applied Biosystems (Foster City, CA) peptide synthesizer Model 433A. Preloaded PEG-PS (polyethylenglycol polysterene) resins (0.15-0.2 mmol/g loading) (per Septive Biosystems, Warrington, UK) were used as solid phase to build up the peptides. Chemicals were purchased from Applied Biosystems. Coupling of amino acids was confirmed by conductivity monitoring in a feedback control system. One cysteine residue was added to each peptide at the N- or C-terminus to facilitate coupling of the peptides to carriers. Peptides were cleaved from the resins with a mixture of : 250 μ l dest. water, 250 μ l Triisopropylsilan (Flukan, Buchs, Switzerland), 9.5 ml TFA for 2 h and precipitated in tert-Butylmethylether (Flukan, Buchs, Switzerland). The identity of the

peptides was checked by mass-spectrometry and they were purified to >90% purity by preparative HPLC (PiChem, Graz, Austria) (Focke M, Mahler V, Ball T, Sperr WR, Majlesi Y, Valent P, Kraft D, Valenta R. Nonanaphylactic synthetic peptides derived from B cell epitopes of the major grass pollen allergen, Phl p 1, for allergy vaccination. *FASEB J.* 2001, 15: 2042-2044.

The allergenic activity of the Phl p 2-derived peptides was evaluated by comparing the IgE-reactivity of complete rPhl p 2 with the peptides by dot blot analysis (Figure 1). Nitrocellulose-dotted Phl p 2-derived peptides (P1-P3), an immunologically unrelated major grass pollen allergen, rPhl p 5 (Vrtala S, Sperr WR, Reimitzer I, van Ree R, Laffer S, Müller WD, Valent P, Lechner K, Rumpold H, Kraft D, Scheiner O, Valenta R. cDNA cloning of a major allergen from timothy grass (*Phleum pratense*) pollen; characterization of the recombinant Phl p V allergen. *J.Immunol.* 1993, 151: 4773-4781), and for control purposes, human serum albumin as well as a control peptide were exposed to sera from grass pollen allergic patients and to serum from a non-allergic individual.

Bound IgE antibodies were detected as described previously (Valenta R, Duchêne M, Ebner C, Valent P, Sillaber C, Deviller P, Ferreira F, Tejkl M, Edelmann H, Kraft D, Scheiner O. Profilins constitute a novel family of functional plant pan-allergens. *J.Exp.Med.* 1992, 175: 377-385). Sera from all 35 grass pollen allergic patients showed IgE reactivity to nitrocellulose-dotted rPhl p 2 but no serum reacted with any of the three Phl p 2-derived peptides (Figure 1). Serum from the non-allergic individual displayed no IgE reactivity to any of the peptides or proteins.

Example 2: Characterization of the recombinant Phl p 2 mosaic protein.

A recombinant Phl p 2 mosaic protein was obtained by recombination of the three Phl p 2-derived peptides in altered sequence. This mosaic protein was created under the assumption that recombination of three non-allergenic Phl p 2 fragments in altered order will deliver a mosaic protein with disrupted three-dimensional structure and consequently reduced allergenic activity. In addition it was expected that the mosaic protein will exhibit better immunogenicity compared to the individual smaller peptide units and preserve the entire primary amino acid sequence of Phl p 2 thus containing the relevant T cell epitopes of Phl p 2.

Figure 2 shows the assembly of the three peptides in the natural Phl p 2 allergen compared to that of the Phl p 2 mosaic protein. In order to compare the two proteins a recombinant Phl p 2 containing a C-terminal hexahistidine tail and a recombinant Phl p 2 mosaic protein was produced which also contained a C-terminal hexahistidine tail (Figure 2) to allow the purification of both proteins by Nickel affinity chromatography (Quiagen, Hilden, Germany).

The recombinant Phl p 2 mosaic was constructed by PCR-based gene amplification of cDNAs coding for the three peptides in the order shown in Figure 2 using the primers displayed in Figure 3 and the Phl p 2-encoding cDNA (Dolecek C, Vrtala S, Laffer S, Steinberger P, Kraft D, Scheiner O, Valenta R. Molecular characterization of Phl p II, a major timothy grass (*Phleum pratense*) pollen allergen. *FEBS Lett.* 1993, 335: 299-304) as template as described (Linhart B, Jahn-Schmid B, Verdino P, Keller W, Ebner C, Kraft D, Valenta R. Combination vaccines for the treatment of grass pollen allergy consisting of genetically engineered hybrid molecules with increased immunogenicity. *FASEB J.* 2002, 16: 1301-1303).

Figure 4 shows the DNA and deduced amino acid sequence of the recombinant Phl p 2 mosaic protein. The his-tagged mosaic protein is encoded by a DNA of 309 bp coding for a protein with a calculated molecular of 11769 Da almost identical to the his-tagged recombinant Phl p 2 allergen (11784 Da).

The cDNA coding for a his-tagged rPhl p 2 allergen was obtained by PCR using a combination of the 5' primer P2/1 (SEQ ID NO:6) and the 3' primer P2/7 (SEQ ID NO:12): CGC GAA TTC TCA GTG GTG GTG GTG GTG CTC TTC TGG CGC GTA GGT GGC and the cDNA coding for Phl p 2 as a template.

The cDNAs coding for the his-tagged Phl p 2 mosaic and the his-tagged Phl p 2 allergen were separately ligated into Nde I/Eco RI cut plasmids pET17b (Novagen). The DNA sequences of the two plasmid constructs was confirmed by sequence analysis and the recombinant proteins were expressed in *Escherichia coli* BL21 (DE3) (Novagen) by induction with 0.5-mM isopropyl- β -thiogalactopyranoside at an optical density at 600 nm of 0.4 in liquid culture (LB, medium containing 100mg/l ampicillin) for additional 4 hours at 37°C. *E. coli* cells from a 500 ml culture were harvested by centrifugation and prepared for purification under native (rPhl p 2) or denaturing conditions (rPhl p 2 mosaic) according to the manufacturers

advice (Quiagen, Hilden, Germany). Protein samples were analysed for purity by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and protein staining (Fling SP, Gregerson DS. Peptide and protein molecular weight determination by electrophoresis using a high-molarity Tris buffer system without urea. *Anal.Biochem.* 1986, 155:83-88) (Figure 4).

Figure 5 shows the purity of the his-tagged recombinant proteins (rPhl p 2: P2; rPhl p 2 mosaic: P2M). Although the two proteins did not show a completely identical migration behaviour in the SDS-PAGE, mass spectroscopical analysis performed as described by Niederberger V, Hayek B, Vrtala S, Laffer S, Twardosz A, Vangelista L, Sperr WR, Valent P, Rumpold H, Kraft D, Ehrenberger K, Valenta R, Spitzauer S. Calcium-dependent immunoglobulin E recognition of the apo- and calcium-bound form of a cross-reactive two EF-hand timothy grass pollen allergen, Phl p 7. *FASEB J.* 1999, 13: 843-856 showed almost identical molecular weights of the two proteins (rPhl p 2: 11775 Da; rPhl p 2 mosaic: 11770 Da) which were in good agreement with the deduced molecular weights including the methionines at their N-terminus (Figure 6).

Example 3: rPhl p 2 mosaic lacks IgE reactivity and allergenic properties

The IgE binding capacity of purified Phl p 2 mosaic (P2M) was compared with that of Phl p 2 wildtype by dot blot experiments as described for the peptides using sera from twelve timothy grass pollen allergic patients (Figure 7). Sera from all 12 grass pollen allergic patients contained IgE antibodies against rPhl p 2 but no serum exhibited IgE reactivity to the rPhl p 2 mosaic or the negative control, human serum albumin (Figure 7). The strongly reduced allergenic activity of the rPhl p 2 mosaic was further demonstrated by basophil histamine release and skin test experiments. Basophils from a grass pollen allergic patient were enriched by dextran sedimentation and exposed to increasing concentrations of purified rPhl p 2 or rPhl p 2 mosaic as described (Valent P, Besemer J, Muhm M, Majdic O; Lechner K, Bettelhei P. Interleukin 3 activates human blood basophils via high-affinity binding sites. *Proc.Natl.Acad.Sci. USA* 1989, 86: 5542-5546).

Histamine released in the cell free supernatants was determined in triplicates by radioimmuno assay and is expressed as mean percentage of the total histamine content of the cells as described by Valent *et al.*

Figure 8 shows that the rPhl p 2 mosaic (maximal release between 1 and 10 $\mu\text{g/ml}$) exhibited a more than 1000 fold reduced allergenic activity compared to the rPhl p 2 allergen (maximal release 10^{-3} $\mu\text{g/ml}$).

The strongly reduced allergenic activity of rPhl p 2 mosaic was confirmed by skin testing in grass pollen allergic patients (Table 2). SPTs (skin prick tests) were performed on the individuals' forearms. Twenty microliter aliquots containing 5 concentrations of rPhl p 2 and of Phl p 2-derived mosaic P2M (1 $\mu\text{g/ml}$, 2 $\mu\text{g/ml}$, 4 $\mu\text{g/ml}$, 8 $\mu\text{g/ml}$, 16 $\mu\text{g/ml}$) were applied. In addition, standardized skin prick solutions (timothy grass pollen extract and histamine) (Allergopharma, Reinbeck, Germany) were tested. Reactions were recorded 20 minutes after SPT by photography and by transferring the ballpoint pen-surrounded wheal area with a scotch tape to paper. The mean wheal diameter (Dm) was calculated by measuring the maximal longitudinal and transversal diameter and dividing their sum by 2 as described by Focke *et al.*, 2001.

rPhl p 2 induced strong wheal reactions already at the lowest concentration tested, i.e., 1 $\mu\text{g/ml}$, whereas rPhl p 2 mosaic induced only mild wheal reactions at the maximal concentrations tested (i.e., 8-16 $\mu\text{g/ml}$) thus confirming the reduced allergenic activity of the mosaic protein.

Example 4: Immunization with the rPhl p 2 mosaic induces IgG antibodies that recognize rPhl p 2 wildtype and inhibit allergic patients IgE binding to Phl p 2.

In order to test whether immunization with Phl p 2 mosaic and rPhl p 2 mosaic will induce IgG antibodies that react with natural Phl p 2, rabbits were immunized with rPhl p 2 mosaic, KLH-coupled rPhl p 2 mosaic or rPhl p 2 using Freund's adjuvant as described by Focke *et al.*

The reactivity of rabbit IgG antibodies with rPhl p 2 was studied by dot blot experiments (Figure 9). Phl p 2 wildtype (P2) as well as the corresponding immunogen Phl p 2 mosaic (P2M) were dotted onto nitrocellulose-strips (1 $\mu\text{g/ dot}$). Nitrocelluloses were exposed to the rabbits preimmune or immune sera (1:500) and bound rabbit antibodies were detected with a 1:1000 diluted ^{125}I -labeled donkey anti-rabbit antiserum (Amersham Pharmacia Biotech) as described by Valenta *et al.*, 1992.

The rabbit anti-rPhl p 2 mosaic antiserum reacted strongly with the immunogen. (rPhl p 2 mosaic) as well as with the rPhl p 2 allergen (Figure 9). The antibody reactivity was of comparable intensity as that obtained with the antiserum produced by immunization with the KLH-coupled mosaic and stronger than the reactivity induced by immunization with the rPhl p 2 allergen (Figure 9).

Example 6: Measurement of blocking antibodies

It was studied whether IgG antibodies induced by immunization with the rPhl p 2 mosaic inhibit the binding of allergic patients' serum IgE to complete rPhl p 2 by ELISA competition using sera from five grass pollen allergic patients (Table 3). ELISA plates (Nunc Maxisorp, Rokslide, Denmark) were coated with rPhl p 2 (1 µg/ml) and preincubated either with a 1:100 dilution of each of the anti-Phl p 2 mosaic and anti-Phl p 2 antiserum and, for control purposes, with the corresponding preimmunsera. After washing plates were incubated with 1:3 diluted sera from five Phl p 2-sensitized grass pollen allergic patients and bound IgE antibodies were detected with alkaline phosphate conjugated monoclonal rat anti-human IgE antibody (Pharmingen, San Diego, CA), diluted 1:1000. The percentage inhibition of IgE binding achieved by preincubation with the anti- Phl p 2 mosaic and Phl p 2 was calculated as follows: %inhibition of IgE binding= $100 - OD_I / OD_P \times 100$. OD_I and OD_P represent the extinctions after preincubation with the rabbits immune and preimmune serum, respectively as described by Focke *et al.*, 2001.

The anti-Phl p 2 mosaic antibodies inhibited the binding of grass pollen allergic patients IgE binding to Phl p 2 (20.93% average inhibition) albeit to a lower degree as was achieved by preincubation with antibodies induced by immunization with the rPhl p 2 allergen (54.73% average inhibition).

The results of the immunization studies thus show that antibodies raised against the rPhl p 2 mosaic recognize the Phl p 2 wildtype allergen and inhibit allergic patients IgE recognition of Phl p 2.

EPO - Munich
67
21. Jan. 2003

BIOMAY Produktions- und
Handels-Aktiengesellschaft

Claims

- 1) Process for the preparation of an hypoallergenic mosaic antigen derived from an allergen whereby
 - a) in a first step the allergen is split into at least two parts and the IgE reactivity of each part is determined and
 - b) in a second step those parts of the allergen which have no detectable IgE reaction are combined to a mosaic antigen which comprises the amino acids of the allergen but the order of the amino acids of the mosaic antigen is different from that of the naturally occurring allergen.
- 2) Process according to claim 1 wherein in the first step at least two parts of the allergen are prepared by chemical synthesis or by using the polymerase chain reaction and each part of the allergen is separately reacted with serum obtained from allergic individuals and the reactivity of IgE antibodies contained within such serum with each part of the allergen is determined.
- 3) Process according to claims 1 or 2 wherein the order of the parts of the allergen having no substantial reactivity with IgE antibodies obtained from allergic individuals does not correspond with the order of those parts in the naturally occurring allergen insofar as the part normally occurring at the N-terminus and the part normally occurring at the C-terminus are replaced by each other.
- 4) Process according to any of the preceding claims wherein the allergen is a group 2 allergen.
- 5) Process according to any of the preceding claims wherein the allergen is the timothy grass pollen allergen Phl p 2.

- 6) Process according to claim 5 wherein the allergen Phl p 2 is split into three peptides, namely peptide 1 having amino acids 1-33, peptide 2 having amino acids 34-64 and peptide 3 having amino acids 65-96 of the amino acid sequence of naturally occurring Phl p 2 and the mosaic antigen is provided by linking the peptides in the order peptide 1, peptide 3 and peptide 2.
- 7) Mosaic allergen having the amino acid sequence of SEQ ID NO:1.
- 8) DNA sequence having SEQ ID NO:2 coding for the mosaic allergen of claim 7 or a sequence complementary thereto.
- 9) Use of a mosaic allergen obtainable by a process according to any one of claims 1-6 for the preparation of a medicament for the treatment of an allergic reaction.
- 10) Use of a mosaic allergen according to claim 9 wherein the allergic reaction is caused by grass pollen.
- 11) Use of a mosaic allergen according to claim 10 wherein the allergic reaction is caused by timothy grass pollen.
- 12) Use of a mosaic allergen according to claim 11 wherein the allergic reaction is caused by timothy grass pollen Phl p 2.
- 13) Vaccine for the treatment of allergic patients characterized in that it comprises a mosaic allergen obtainable by any process according to claims 1-6 or the mosaic allergen of claim 7.
- 14) Vaccine for the treatment of grass pollen allergic patients characterized in that it comprises a DNA sequence coding for a mosaic antigen obtainable by a process according to any of claims 1-6 or the DNA of claim 8 or sequences complementary to any of these DNA sequences.

Table 1.

	Position	Sequence	Number		Molecular		Isoelectric	
			of aa		weight		point	
Peptide 1	1-33	VPKVTFTVEKGSNEKHLAVLVKYEGLTMAEVELC	34		3765,02		4.87	
Peptide 3	65-96	REHGSDEWVAMTKGEGGVWTFDSEEP LQGPFNC	33		3696,8		4.03	
Peptide 2	34-64	CFRFLTEKGMKNVFDVPEKYTIGATYAPEE	32		3698,91		4.45	

EPO - Munich
67
21. Jan, 2003

Table 2.

Induction of immediate skin reactions with Phl p 2 and Phl p 2 mosaic

Individual 1

mean wheal diameter (mm)		
	P2	P2M
1 µg/ml	9	0
2 µg/ml	10	0
4 µg/ml	11	0
8 µg/ml	14	5
16 µg/ml	10	4
Timothy grass	15	
Histamine	8	

Individual 2

mean wheal diameter (mm)		
	P2	P2M
1 µg/ml	5	0
2 µg/ml	5	0
4 µg/ml	6	0
8 µg/ml	7	0
16 µg/ml	9	3
Timothy grass	10	
Histamine	8	

Table 3.

Rabbit anti P2 mosaic and rabbit anti-rPhl p 2 antibodies
inhibit IgE binding of grass pollen allergic patients to rPhl p 2

		% inhibition	
Patient	anti-P2M	anti-rPhl p 2	
1	39.54	76.93	
2	9.25	63.97	
3	23.20	52.91	
4	14.38	40.86	
5	18.27	38.97	
Mean	20.93	54.73	

Figure 1.




Figure 2.

P 2




Figure 3.

SEQ ID NO:

6 P2/1: 5' - GGA TTT CCA TAT GGT CCC GAA GGT GAC GTT CAC G - 3'

7 P2/2: 5' - GGT GAG GAA CCG GAA GAG CTC CAC CTC CGC CAT GGT - 3'

8 P2/3: 5' - GCG GAG GTG GAG CTC TTC CGG TTC CTC ACC GAG AAG - 3'

9 P2/4: 5' - GGA GCC GTG CTC CCG CTC TTC TGG CGC GTA GGT GGC - 3'

10 P2/5: 5' - TAC GCG CCA GAA GAG CGG GAG CAC GGC TCC GAC GAG - 3'

11 P2/6: 5' - CGC GAA TTC TCA GTG GTG GTG GTG GTG GTT GAA GGG CCC CTG GAG
CGG - 3'




Figure 4.

P2M-Sequence

ATG GTC CCG AAG GTG ACG TTC ACG GTG GAG AAG GGG TCC AAC GAG AAG CAC	51
M V P K V T F T V E K G S N E K H	17
CTG GCG GTG CTG GTG AAG TAC GAG GGG GAC ACC ATG GCG GAG GTG GAG CTC	102
L A V L V K Y E G D T M A E V E L	34
TTC CCG TTC CTC ACC GAG AAG GGC ATG AAG AAC GTC TTC GAC GAC GTC GTC	153
F R F L T E K G M K N V F D D V V	51
CCA GAG AAG TAC ACC ATT GGG GCC ACC TAC GCG CCA GAA GAG CGG GAG CAC	204
P E K Y T I G A T Y A P E E R E H	68
GGC TCC GAC GAG TGG GTC GCC ATG ACC AAG GGG GAG GGC GTG TGG ACG	255
G S D E W V A M T K G E G G V W T	85
TTC GAC AGC GAG GAG CCG CTC CAG GGG CCC TTC AAC CAC CAC CAC CAC CAC	306
F D S E E P L Q G P F N H H H H H	102
CAC	309
H	103

Figure 5.




Figure 6





Figure 7.




Figure 8.





Figure 9.



EPO - Munich
67
21. Jan. 2003

BIOMAY Produktions- und
Handels-Aktiengesellschaft

Abstract

A process for the preparation of an hypoallergenic mosaic antigen derived from an allergen is disclosed whereby

- a) in a first step the allergen is split into at least two parts and the IgE reactivity of each part is determined and
- b) in a second step those parts of the allergen which have no detectable IgE reaction are combined to a mosaic antigen which comprises the amino acids of the allergen but the order of the amino acids of the mosaic antigen is different from that of the naturally occurring allergen.

SEQUENCE LISTING

EPO - Munich
67
21. Jan. 2003

<110> Biomay Produktions- und Handels-Aktiengesellschaft

<120> Process for the preparation of hypoallergenic mosaic antigens

<130> mosaic

<140>

<141>

<160> 12

<170> PatentIn Ver. 2.1

<210> 1

<211> 103

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: rearranged polypeptide sequence

<400> 1

Met Val Pro Lys Val Thr Phe Thr Val Glu Lys Gly Ser Asn Glu Lys
1 5 10 15

His Leu Ala Val Leu Val Lys Tyr Glu Gly Asp Thr Met Ala Glu Val
20 25 30

Glu Leu Phe Arg Phe Leu Thr Glu Lys Gly Met Lys Asn Val Phe Asp
35 40 45

Asp Val Val Pro Glu Lys Tyr Thr Ile Gly Ala Thr Tyr Ala Pro Glu
50 55 60

Glu Arg Glu His Gly Ser Asp Glu Trp Val Ala Met Thr Lys Gly Glu
65 70 75 80

Gly Gly Val Trp Thr Phe Asp Ser Glu Glu Pro Leu Gln Gly Pro Phe
85 90 95

Asn His His His His His His
100

<210> 2
<211> 309
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: rearranged
nucleotide sequence

<400> 2
atggtcccga aggtgacgtt cacggtggag aaggggtcca acgagaagca cctggcggtg 60
ctggtgaagt acgaggggga caccatggcg gaggtggagc tcttccggtt cctcaccgag 120
aagggcatga agaacgtctt cgacgacgtc gtcccagaga agtacaccat tggggccacc 180
tacgcgccag aagagcggga gcacgggtcc gacgagtggg tcgccatgac caagggggag 240
ggcggcgtgt ggacgttcga cagcgaggag ccgctccagg ggcccttcaa ccaccaccac 300
caccaccac 309

<210> 3
<211> 34
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: polypeptide

<400> 3
Val Pro Lys Val Thr Phe Thr Val Glu Lys Gly Ser Asn Glu Lys His
1 5 10 15
Leu Ala Val Leu Val Lys Tyr Glu Gly Asp Thr Met Ala Glu Val Glu
20 25 30
Leu Cys

<210> 4
<211> 33
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: polypeptide

<400> 4
Arg Glu His Gly Ser Asp Glu Trp Val Ala Met Thr Lys Gly Glu Gly
1 5 10 15

Gly Val Trp Thr Phe Asp Ser Glu Glu Pro Leu Gln Gly Pro Phe Asn
 20 25 30

Cys

<210> 5

<211> 32

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: polypeptide

<400> 5

Cys Phe Arg Phe Leu Thr Glu Lys Gly Met Lys Asn Val Phe Asp Asp
 1 5 10 15

Val Val Pro Glu Lys Tyr Thr Ile Gly Ala Thr Tyr Ala Pro Glu Glu
 20 25 30

<210> 6

<211> 34

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: primer

<400> 6

ggatttccat atggtcccga aggtgacgtt cacg

34

<210> 7

<211> 36

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: primer

<400> 7

ggtgaggaac cggaagagct ccacctccgc catggt

36

<210> 8

<211> 36

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: primer

<400> 8

gcggaggtgg agctcttccg gttcctcacc gagaag

36

<210> 9

<211> 36

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: primer

<400> 9

ggagccgtgc tcccgtctt ctggcgcgta ggtggc

36

<210> 10

<211> 36

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: primer

<400> 10

tacgcgccag aagagcggga gcacggctcc gacgag

36

<210> 11

<211> 51

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: primer

<400> 11

cgcggaattct cagtgggtggt ggtgggtggtg gttgaagggc ccctggagcg g

51

<210> 12

<211> 51

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: primer

<400> 12

cgcggaattct cagtgggtggt ggtgggtggtg ctcttctggc gcgtaggtgg c

51

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

☒ **BLACK BORDERS**

☒ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**

☒ **FADED TEXT OR DRAWING**

☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**

☐ **SKEWED/SLANTED IMAGES**

☒ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**

☐ **GRAY SCALE DOCUMENTS**

☐ **LINES OR MARKS ON ORIGINAL DOCUMENT**

☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**

☐ **OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.